Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C.
Modi
Marlene W
MW
Department of Clinical Pharmacology, Hoffmann-La Roche, Inc., Nutley, NJ, USA.
Lamb
Matthew W
MW
Shiomi
Mari
M
D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005079:Excipients; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D000998:Antiviral Agents; D005079:Excipients; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a